Mammaglobin&nbsp;B may be a prognostic biomarker of uterine corpus endometrial cancer

Li,Jie; Xu,Wenwen; Zhu,Yuxi

doi:10.3892/ol.2020.12118

Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer

Authors:
- Jie Li
- Wenwen Xu
- Yuxi Zhu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: September 18, 2020 https://doi.org/10.3892/ol.2020.12118
Article Number: 255
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mammaglobin B, also referred to as secretoglobin family 2A member 1 (SCGB2A1), has been reported to be highly expressed in uterine corpus endometrial cancer (UCEC) compared with in the normal endometrium. However, the prognostic value of SCGB2A1 in UCEC remains unclear. The Oncomine, The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium databases were used to explore the differential expression of SCGB2A1. Furthermore, data of patients with UCEC were downloaded from TCGA, and logistic regression analysis, survival analysis, univariate and multivariate analyses, and nomogram construction were performed to identify its prognostic value in UCEC. Additionally, gene set enrichment analysis (GSEA) was utilized to estimate the mechanisms of SCGB2A1 in UCEC. Finally, immune infiltration of SCGB2A1 in UCEC was analyzed using the Tumor Immune Estimation Resource. Decreased mRNA and protein expression levels of SCGB2A1 were significantly associated with poor prognostic clinicopathological characteristics (all P<0.05). Additionally, low expression levels of SCGB2A1 were associated with decreased survival of patients with UCEC compared with high expression levels of SCGB2A1. Furthermore, the independent prognostic value of SCGB2A1 in UCEC was identified by univariate and multivariate analyses. A nomogram based on 6 variables, including SCGB2A1 expression, was developed for the estimation of the 1‑, 3‑, and 5‑year survival probability in UCEC. Additionally, GSEA suggested that the vascular endothelial growth factor, PTEN, platelet‑derived growth factor, DNA repair, KRAS signaling, and PI3K‑AKT‑mTOR signaling pathways were differentially enriched in the low SCGB2A1 expression phenotype. Finally, high infiltration levels of CD8+ T cells were associated with SCGB2A1 in UCEC and this was associated with prognosis. The present results indicated that SCGB2A1 may be a promising independent prognostic factor in UCEC. These signaling pathways may be crucial for the regulation of UCEC via SCGB2A1.

View Figures

View References

1	Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K and Veneris JL: Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 69:258–279. 2019.PubMed/NCBI
4	Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al: ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41. 2016. View Article : Google Scholar : PubMed/NCBI
5	Reijnen C, IntHout J, Massuger LFAG, Strobbe F, Küsters-Vandevelde HVN, Haldorsen IS, Snijders MPLM and Pijnenborg JMA: Diagnostic accuracy of clinical biomarkers for preoperative prediction of lymph node metastasis in endometrial carcinoma: A systematic review and meta-analysis. Oncologist. 24:e880–e890. 2019. View Article : Google Scholar : PubMed/NCBI
6	Lee YC, Lheureux S and Oza AM: Treatment strategies for endometrial cancer: Current practice and perspective. Curr Opin Obstet Gynecol. 29:47–58. 2017. View Article : Google Scholar : PubMed/NCBI
7	Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, et al: Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 37:2317–2328. 2019. View Article : Google Scholar : PubMed/NCBI
8	Ni J, Kalff-Suske M, Gentz R, Schageman J, Beato M and Klug J: All human genes of the uteroglobin family are localized on chromosome 11q12.2 and form a dense cluster. Ann N Y Acad Sci. 923:25–42. 2000. View Article : Google Scholar : PubMed/NCBI
9	Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, et al: Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer. 9:2532009. View Article : Google Scholar : PubMed/NCBI
10	Becker RM, Darrow C, Zimonjic DB, Popescu NC, Watson MA and Fleming TP: Identification of mammaglobin B, a novel member of the uteroglobin gene family. Genomics. 54:70–78. 1998. View Article : Google Scholar : PubMed/NCBI
11	Wong RL, Wang Q, Treviño LS, Bosland MC, Chen J, Medvedovic M, Prins GS, Kannan K, Ho SM and Walker CL: Identification of secretaglobin Scgb2a1 as a target for developmental reprogramming by BPA in the rat prostate. Epigenetics. 10:127–134. 2015. View Article : Google Scholar : PubMed/NCBI
12	Ouellette RJ, Richard D and Maicas E: RT-PCR for mammaglobin genes, MGB1 and MGB2, identifies breast cancer micrometastases in sentinel lymph nodes. Am J Clin Pathol. 121:637–643. 2004. View Article : Google Scholar : PubMed/NCBI
13	Hassan EM, Willmore WG, McKay BC and DeRosa MC: In vitro selections of mammaglobin A and mammaglobin B aptamers for the recognition of circulating breast tumor cells. Sci Rep. 7:144872017. View Article : Google Scholar : PubMed/NCBI
14	Aihara T, Fujiwara Y, Miyake Y, Okami J, Okada Y, Iwao K, Sugita Y, Tomita N, Sakon M, Shiozaki H and Monden M: Mammaglobin B gene as a novel marker for lymph node micrometastasis in patients with abdominal cancers. Cancer Lett. 150:79–84. 2000. View Article : Google Scholar : PubMed/NCBI
15	Fiegl M, Haun M, Massoner A, Krugmann J, Müller-Holzner E, Hack R, Hilbe W, Marth C, Duba HC, Gastl G and Grünewald K: Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions. J Clin Oncol. 22:474–483. 2004. View Article : Google Scholar : PubMed/NCBI
16	Munakata K, Uemura M, Takemasa I, Ozaki M, Konno M, Nishimura J, Hata T, Mizushima T, Haraguchi N, Noura S, et al: SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance. Int J Oncol. 44:1521–1528. 2014. View Article : Google Scholar : PubMed/NCBI
17	Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, et al: Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: Implications for ovarian cancer immunotherapy. Br J Cancer. 109:462–471. 2013. View Article : Google Scholar : PubMed/NCBI
18	Tassi RA, Bignotti E, Falchetti M, Calza S, Ravaggi A, Rossi E, Martinelli F, Bandiera E, Pecorelli S, Santin AD, et al: Mammaglobin B expression in human endometrial cancer. Int J Gynecol Cancer. 18:1090–1096. 2008. View Article : Google Scholar : PubMed/NCBI
19	Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
20	Boja E, Tezak Z, Zhang B, Wang P, Johanson E, Hinton D and Rodriguez H: Right data for right patient-a precisionFDA NCI-CPTAC Multi-omics mislabeling challenge. Nat Med. 24:1301–1302. 2018. View Article : Google Scholar : PubMed/NCBI
21	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
22	Chen F, Chandrashekar DS, Varambally S and Creighton CJ: Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 10:56792019. View Article : Google Scholar : PubMed/NCBI
23	Huo Q, Li Z, Cheng L, Yang F and Xie N: SIRT7 is a prognostic biomarker associated with immune infiltration in luminal breast cancer. Front Oncol. 10:6212020. View Article : Google Scholar : PubMed/NCBI
24	Yang H, Gao S, Chen J and Lou W: UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma. Cancer Cell Int. 20:2342020. View Article : Google Scholar : PubMed/NCBI
25	Chen W, Dai X, Chen Y, Tian F, Zhang Y, Zhang Q and Lu J: Significance of STAT3 in immune infiltration and drug response in cancer. Biomolecules. 10:8342020. View Article : Google Scholar
26	Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017. View Article : Google Scholar : PubMed/NCBI
27	Tomczak K, Czerwinska P and Wiznerowicz M: The cancer genome atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn). 19A:A68–A77. 2015.
28	Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al: The landscape of somatic copy-number alteration across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
29	Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R and Getz G: GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12:R412011. View Article : Google Scholar : PubMed/NCBI
30	Sepulveda JL: Using R and Bioconductor in clinical genomics and transcriptomics. J Mol Diagn. 22:3–20. 2020. View Article : Google Scholar : PubMed/NCBI
31	Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 34:267–273. 2003. View Article : Google Scholar : PubMed/NCBI
32	Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P and Mesirov JP: Molecular signatures database (MSigDB) 3.0. Bioinformatics. 27:1739–1740. 2011. View Article : Google Scholar : PubMed/NCBI
33	Dellinger TH, Smith DD, Ouyang C, Warden CD, Williams JC and Han ES: L1CAM is an independent predictor of poor survival in endometrial cancer-An analysis of the cancer genome atlas (TCGA). Gynecol Oncol. 141:336–340. 2016. View Article : Google Scholar : PubMed/NCBI
34	Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, Onda T, Nakagawa S, Matsumoto K, Kawana K and Taketani Y: PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res. 7:2636–2642. 2001.PubMed/NCBI
35	Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, et al: The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet. 48:848–855. 2016. View Article : Google Scholar : PubMed/NCBI
36	Song MS, Salmena L and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 13:283–296. 2012. View Article : Google Scholar : PubMed/NCBI
37	Witek L, Janikowski T, Bodzek P, Olejek A and Mazurek U: Expression of tumor suppressor genes related to the cell cycle in endometrial cancer patients. Adv Med Sci. 61:317–324. 2016. View Article : Google Scholar : PubMed/NCBI
38	Chen J, Zhao KN, Li R, Shao R and Chen C: Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer. Curr Med Chem. 21:3070–3080. 2014. View Article : Google Scholar : PubMed/NCBI
39	Tu Z, Gui L, Wang J, Li X, Sun P and Wei L: Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor. Gynecol Oncol. 101:274–279. 2006. View Article : Google Scholar : PubMed/NCBI
40	McDonald ME and Bender DP: Endometrial cancer: Obesity, genetics, and targeted agents. Obstet Gynecol Clin North Am. 46:89–105. 2019. View Article : Google Scholar : PubMed/NCBI
41	Lee II, Maniar K, Lydon JP and Kim JJ: Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells. Oncogene. 35:5191–5201. 2016. View Article : Google Scholar : PubMed/NCBI
42	Vassileva V, Millar A, Briollais L, Chapman W and Bapat B: Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res. 62:4095–4099. 2002.PubMed/NCBI
43	Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:843–845. 1992. View Article : Google Scholar : PubMed/NCBI
44	Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 69 Suppl 3:S4–S10. 2005. View Article : Google Scholar
45	Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M and Yoshihara T: Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol. 80:181–188. 2001. View Article : Google Scholar : PubMed/NCBI
46	Di Cello A, Di Sanzo M, Perrone FM, Santamaria G, Rania E, Angotti E, Venturella R, Mancuso S, Zullo F, Cuda G and Costanzo F: DJ-1 is a reliable serum biomarker for discriminating high-risk endometrial cancer. Tumour Biol. 39:10104283177057462017. View Article : Google Scholar : PubMed/NCBI
47	Bernstein JL, Godbold JH, Raptis G, Watson MA, Levinson B, Aaronson SA and Fleming TP: Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res. 11:6528–6535. 2005. View Article : Google Scholar : PubMed/NCBI
48	Holub K and Biete A: New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. BMC Cancer. 18:12802018. View Article : Google Scholar : PubMed/NCBI
49	Ning C, Xie B, Zhang L, Li C, Shan W, Yang B, Luo X, Gu C, He Q, Jin H, et al: Infiltrating macrophages induce ERα expression through an IL17A-mediated epigenetic mechanism to sensitize endometrial cancer cells to estrogen. Cancer Res. 76:1354–1366. 2016. View Article : Google Scholar : PubMed/NCBI
50	Chang WC, Li CH, Huang SC, Chang DY, Chou LY and Sheu BC: Clinical significance of regulatory T cells and CD8⁺ effector populations in patients with human endometrial carcinoma. Cancer. 116:5777–5788. 2010. View Article : Google Scholar : PubMed/NCBI
51	Kondratiev S, Sabo E, Yakirevich E, Lavie O and Resnick MB: Intratumoral CD8⁺ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 10:4450–4456. 2004. View Article : Google Scholar : PubMed/NCBI
52	Kelly MG, Francisco AM, Cimic A, Wofford A, Fitzgerald NC, Yu J and Taylor RN: Type 2 endometrial cancer is associated with a high density of tumor-associated macrophages in the stromal compartment. Reprod Sci. 22:948–953. 2015. View Article : Google Scholar : PubMed/NCBI
53	Jing X, Peng J, Dou Y, Sun J, Ma C, Wang Q, Zhang L, Luo X, Kong B, Zhang Y, et al: Macrophage ERα promoted invasion of endometrial cancer cell by mTOR/KIF5B-mediated epithelial to mesenchymal transition. Immunol Cell Biol. 97:563–576. 2019. View Article : Google Scholar : PubMed/NCBI